PrenaLab UG (limited liability) was founded in April 2014 by Dr. Martin Burow and Dipl.-Ing Julian Kamhieh-Milz. The co-founders successfully received governmental funding (EXIST, BMWi and Berlin Institute for Health Translation Fund) and have built up a team of professionals with the aim of developing a new and innovative assay of diagnosing Trisomy 21 in a non-invasive manner that is both easy and rapid.
Based on biomarker profiles obtained from maternal blood and the envisioned low-cost of the assay, our diagnostic test is aimed to be affordable for all pregnant women who wish to obtain additional information concerning their pregnancy.
The team is also comprised of Dr. Omid Khorramshahi, a bioinformatician and molecular biologicst; Dr. Reham Moftah, a Physician who has a PhD in human genetics and aneuploidies; and Ms. Dagmar Ogrocki, a biotechnologist with a Master's Degree.
We are currently affiliated with the Charité University - Medicine Berlin.
We are in the process of developing a rapid diagnostic test, with results obtainable within 6 hoursRead More
Our test will be easy-to-perform with standard laboratory equipmentRead More
We offer an inexpensive alternative to other diagnostic assays.Read More
Our test can be easily implemented in small and large routine diagnostic laboratories.Read More
For the further expansion of our business, PrenaLab UG requires profit participating loans to enter the market with a product within a minimum amount of time.
This is your chance to participate in our success.
If successful, you will have the opportunity to double your investment within a period of 5 years.
Please click here for further information or download the PDF file.
Traditional invasive diagnostic techniques such as chorionic villus sampling (CVS) and amniocentesis (AC) are associated with a 0.3–3.0% foetal loss due to the invasive nature of these approaches. Isolated cells require cultivation for a period of 1–2 weeks prior to chromosomal analysis. The turnaround time is approximately 10–14 days.
The new non-invasive prenatal diagnostic (NIPD) test avoids the risk of foetal loss by the collection of maternal blood. However, most NIPD tests depend on Next Generation Sequencing (NGS), with a run taking of at least 3 days. The mean turnaround time is 10 days and ranges between 5 and 14 days.
We are developing a rapid assay with the aim of results becoming available within several hours, and reports generated within 24 hours. The developed NIPD test will be comparably accurate with current techniques applied.
Invasive procedures require time-consuming cell culture and various advanced genome analysing techniques such as caryogramm analysis, fluorescence in situ hybridization (FISH), or array-based comparative genomic hybridization (array-CGH).
Next Generation Sequencing (NGS) - based techniques require quantification of the foetal fraction, DNA isolation, library preparation, NGS, intensive bioinformatic analysis, as well as quality assurance of the data prior to reporting.
In contrast, PrenaLab will be developing an assay that is both easy-to-perform and rapid, that can also be performed in non-specialised diagnostic laboratories with minimal hands-on time.
Current prices for NGS-based approaches range from 500-900 €, which is unaffordable for most pregnant women, even in industrialised countries. This gap harbours a risk of social injustice in this health sector. Array-based approaches will cost approximately 350-400 € per sample.
PrenaLab has the ambition of developing an affordable and accurate non-invasive diagnostic test, with a final price not exceeding 180 €. We hope that more women will be able to employ a risk-free alternative to invasive procedures.
Invasive procedures, NGS-based and the new array-based technologies are not kitable, but are offered as a service from specialised laboratories. Due to the implementation of the new non-invasive tests based on cell-free foetal DNA, less invasive investigations are being performed.
This is a positive trend as this results in fewer foetuses being at risk of invasive procedures. In turn, this has resulted in an increasing number of cytogenetic laboratories loosing their commercial basis.
We are developing a new and innovative diagnostic kit that can be performed in every laboratory, with the generation of in-house reports.